Sebastien Haneuse

Sebastien Haneuse

Auto-generated profile, based on publicly available information

Sebastien Haneuse

Harvard T.H. Chan School of Public Health, Boston, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2019 in JAMA
Verified
Journal Article
Open access
PDF file
SHSebastien Haneuse
Sebastien Haneuse
TVTyler J. VanderWeele
Tyler J. VanderWeele
DADavid Arterburn
David Arterburn
Randomized trials serve as the standard for comparative studies of treatment effects. In many settings, it may not be feasible or ethical to conduct a randomized study,1 and researchers may pursue observational studies to better understand clinical outcomes. A central limitation of observational studies is the potential for confounding bias that arises because treatment assignment is not random. Thus, the observed associations may be attributable to differences other than the treatment being investigated and causality cannot be assumed.

2 March 2020 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
AMAya A. Mitani
Aya A. Mitani
SHSebastien Haneuse
Sebastien Haneuse
The age of big data is in full swing, with researchers in both clinical medicine and public health seeking to take advantage of the increasing availability of m

31 August 2016 in eGEMs (Generating Evidence & Methods to improve patient outcomes)
Verified
Journal Article
Open access
PDF file
SHSebastien Haneuse
Sebastien Haneuse
MDMichael Daniels
Michael Daniels
Electronic health records (EHR) data are increasingly seen as a resource for cost-effective comparative effectiveness research (CER). Since EHR data are collected primarily for clinical and/or billing purposes, their use for CER requires consideration of numerous methodologic challenges including the potential for confounding bias, due to a lack of randomization, and for selection bias, due to missing data. In contrast to the recent literature on confounding bias in EHR-based CER, virtually no attention has been paid to selection bias possibly due to the belief that standard methods for missing data can be readily-applied. Such methods, however, hinge on an overly simplistic view of the available/missing EHR data, so that their application in the EHR setting will often fail to completely control selection bias. Motivated by challenges we face in an on-going EHR-based comparative effectiveness study of choice of antidepressant treatment and long-term weight change, we propose a new general framework for selection bias in EHR-based CER. Crucially, the framework provides structure within which researchers can consider the complex interplay between numerous decisions, made by patients and health care providers, which give rise to health-related information being recorded in the EHR system, as well as the wide variability across EHR systems themselves. This, in turn, provides structure within which: (i) the transparency of assumptions regarding missing data can be enhanced, (ii) factors relevant to each decision can be elicited, and (iii) statistical methods can be better aligned with the complexity of the data.

1 February 2021 in JAMA Network Open
Verified
Journal Article
Closed access
PDF file
SHSebastien Haneuse
Sebastien Haneuse
DADavid Arterburn
David Arterburn
MDMichael J. Daniels
Michael J. Daniels
Missing data are a pervasive problem in clinical and public health research, affecting both randomized trials and observational studies. Reasons for missing dat

11 August 2020 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MSMark J. Siedner
Mark J. Siedner
GHGuy Harling
Guy Harling
ZRZahra Reynolds
Zahra Reynolds
RGRebecca F. Gilbert
Rebecca F. Gilbert
SHSebastien Haneuse
Sebastien Haneuse
ATAlexander C. Tsai
Alexander C. Tsai
Social distancing measures to address the US coronavirus disease 2019 (COVID-19) epidemic may have notable health and social impacts. We conducted a longitudinal pretest–posttest comparison group study to estimate the change in COVID-19 case growth before versus after implementation of statewide social distancing measures in the US. The primary exposure was time before (14 days prior to, and through 3 days after) versus after (beginning 4 days after, to up to 21 days after) implementation of the first statewide social distancing measures. Statewide restrictions on internal movement were examined as a secondary exposure. The primary outcome was the COVID-19 case growth rate. The secondary outcome was the COVID-19-attributed mortality growth rate. All states initiated social distancing measures between March 10 and March 25, 2020. The mean daily COVID-19 case growth rate decreased beginning 4 days after implementation of the first statewide social distancing measures, by 0.9% per day (95% CI −1.4% to −0.4%; P < 0.001). We did not observe a statistically significant difference in the mean daily case growth rate before versus after implementation of statewide restrictions on internal movement (0.1% per day; 95% CI −0.04% to 0.3%; P = 0.14), but there is substantial difficulty in disentangling the unique associations with statewide restrictions on internal movement from the unique associations with the first social distancing measures. Beginning 7 days after social distancing, the COVID-19-attributed mortality growth rate decreased by 2.0% per day (95% CI −3.0% to −0.9%; P < 0.001). Our analysis is susceptible to potential bias resulting from the aggregate nature of the ecological data, potential confounding by contemporaneous changes (e.g., increases in testing), and potential underestimation of social distancing due to spillover effects from neighboring states. Statewide social distancing measures were associated with a decrease in the COVID-19 case growth rate that was statistically significant. Statewide social distancing measures were also associated with a decrease in the COVID-19-attributed mortality growth rate beginning 7 days after implementation, although this decrease was no longer statistically significant by 10 days.

1 April 2016 in Medical Care
Verified
Journal Article
Closed access
SHSebastien Haneuse
Sebastien Haneuse
Comparative effectiveness research (CER) aims to provide patients and physicians with evidence-based guidance on treatment decisions. As researchers conduct CER they face myriad challenges. Although inadequate control of confounding is the most-often cited source of potential bias, selection bias that arises when patients are differentially excluded from analyses is a distinct phenomenon with distinct consequences: confounding bias compromises internal validity, whereas selection bias compromises external validity. Despite this distinction, however, the label “treatment-selection bias” is being used in the CER literature to denote the phenomenon of confounding bias. Motivated by an ongoing study of treatment choice for depression on weight change over time, this paper formally distinguishes selection and confounding bias in CER. By formally distinguishing selection and confounding bias, this paper clarifies important scientific, design, and analysis issues relevant to ensuring validity. First is that the 2 types of biases may arise simultaneously in any given study; even if confounding bias is completely controlled, a study may nevertheless suffer from selection bias so that the results are not generalizable to the patient population of interest. Second is that the statistical methods used to mitigate the 2 biases are themselves distinct; methods developed to control one type of bias should not be expected to address the other. Finally, the control of selection and confounding bias will often require distinct covariate information. Consequently, as researchers plan future studies of comparative effectiveness, care must be taken to ensure that all data elements relevant to both confounding and selection bias are collected.